The global Antibody-drug Conjugate for Cancer market was valued at US$ 874 million in 2022 and is projected to reach US$ 1189.2 million by 2029, at a CAGR of 4.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Antibody-drug Conjugate for Cancer market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Antibody-drug Conjugate for Cancer market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Antibody-drug Conjugate for Cancer market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugate for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugate for Cancer. This report contains market size and forecasts of Antibody-drug Conjugate for Cancer in global, including the following market information:
- Global Antibody-drug Conjugate for Cancer Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
North America is the largest market with about 59% market share. Europe is follower, accounting for about 27% market share.
The key players are ImmunoGen, Seattle Genetics, Roche, Takeda etc. Takeda is the largest manufacturer with about 57% revenue market share.
We surveyed the Antibody-drug Conjugate for Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antibody-drug Conjugate for Cancer Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Antibody-drug Conjugate for Cancer Market Segment Percentages, by Type, 2022 (%)
- Hematological Malignancies Drugs
- Solid Tumor Drugs
Global Antibody-drug Conjugate for Cancer Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Antibody-drug Conjugate for Cancer Market Segment Percentages, by Application, 2022 (%)
Global Antibody-drug Conjugate for Cancer Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Antibody-drug Conjugate for Cancer Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Antibody-drug Conjugate for Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Antibody-drug Conjugate for Cancer revenues share in global market, 2022 (%)
key players include:
- Gilead Sciences
- Roche
- Pfizer
- Takeda
- Seagen
- Innate Pharma
- AstraZeneca
- GSK
- Rakuten Medical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Antibody-drug Conjugate for Cancer, market overview.
Chapter 2: Global Antibody-drug Conjugate for Cancer market size in revenue.
Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antibody-drug Conjugate for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
